Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member

• Subject to her election at the AGM, Claudia will also be appointed Vice-Chair of the Board and a member of the Remuneration Committee
• Jürgen Steinemann and Barbara Richmond will not stand for re-election at the 2026 AGM, as they reach their maximum tenures on the Lonza Board of Directors

Basel, Switzerland, 3 October 2025 – Today, the Lonza Board of Directors announced the nomination of Claudia Süssmuth-Dyckerhoff as an Independent Member of the Board. The Board will propose Claudia’s election to shareholders at the Lonza Group Annual General Meeting (AGM) in May 2026. Subject to her election at the AGM, Claudia will also be appointed Vice-Chair of the Board and a member of the Remuneration Committee. 

Claudia has served on the Boards of several listed companies across a range of sectors. Since 2016, Claudia has been a member of the Board of Directors for Roche Holdings, and has served on the Audit, Governance and Sustainability Committee. She also serves on the Boards of Prudential Corporation, Clariant AG, Ramsay Health Care and Quest Global. Claudia previously spent two decades in executive roles at McKinsey & Company with a focus on global healthcare and Asia. 

Following their twelve-year tenures with Lonza, Jürgen Steinemann and Barbara Richmond will not stand for re-election at the 2026 AGM. Jürgen has served as Vice-Chair of the Board since 2024, and is also currently a member of the Renumeration Committee and the Nomination and Governance Committee. Barbara currently serves as the Chair of the Audit and Compliance Committee. 

The planned Board composition for 2026 promotes long-term succession planning, as Claudia will be nominated as Vice-Chair of the Board and a member of the Remuneration Committee, while Marion Helmes will transition from member to Chair of the Audit and Compliance Committee, succeeding Barbara Richmond. These nominations demonstrate a structured approach to continuity and succession, which reflects the Lonza Board’s focus on ensuring robust governance.

Jean-Marc Huët, Chairman of the Board, Lonza, commented: “On behalf of the Board, I am delighted to congratulate Claudia on her nomination. Claudia has extensive international experience in healthcare and life sciences and an outstanding track record of Board membership in listed companies. This experience is relevant to our industry and business, making her an invaluable addition to the Board. I am also very thankful to Barbara and Jürgen for their continued service on the Board until the AGM in 2026. They have both contributed leadership experience and financial acumen to Lonza. On a personal level, I am very grateful for their collaboration, dedication and humor, all of which have been highly valued by the Board.”

Note to Editors:
The following materials are available for download:

• Claudia’s biography
• Claudia’s headshot

About Lonza

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of more than 19,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. 

Our company generated sales of CHF 3.6 billion with a CORE EBITDA of CHF 1.1 billion in Half-Year 2025.

Find out more at www.lonza.com

Lonza Contact Details

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
daniel.buchta@lonza.com

For media inquiries: media@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes.

Privacy Policy link

To immediately delete all the data